Dyclonine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Dyclonine: From Topical Anesthesia to Bronchitis
One-Sentence Summary
Dyclonine is a topical local anesthetic marketed in the US as oral and skin-surface products such as lozenges, liquids and dental solutions. The TxGNN model predicts it may be effective for bronchitis, but this is a model prediction only, with 0 clinical trials and 0 publications supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Topical local anesthesia (the approved indication text is not listed in the licence records) |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the source record. Dyclonine is generally understood to be a topical local anesthetic that blocks voltage-gated sodium channels, and its use in topical products is established.
A theoretical link to bronchitis would be modulation of airway sensory nerves or the cough reflex. This link is speculative. There are no clinical or literature data showing that dyclonine affects cough or airway inflammation. The high TxGNN score most likely reflects proximity in the knowledge graph rather than a demonstrated drug effect.
The available formulations (lozenge, liquid, dental solution) are for oral or skin-surface use, and no route-compatibility assessment has been done for delivery to the bronchial airways. Exposure at the target site is therefore unclear.
Other predictions in the same candidate list, such as dermatomyositis variants, peptic ulcer disease and irritable bowel syndrome, also have no supporting evidence. The one exception is a single 1996 paper on IBS visceral hypersensitivity (PMID 8907258). It does not provide drug-specific evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA200480 | DycloPro (Septodont Inc) | Solution | Not listed |
| M022 | Sucrets Sore Throat Wild Cherry (Insight Pharmaceuticals LLC) | Lozenge | Not listed |
| M003 | Leader Liquid Bandage (Cardinal Health 110, Inc.) | Liquid | Not listed |
| M003 | Benzethonium chloride Plus Dyclonine hydrochloride (AmerisourceBergen Drug Corporation) | Liquid | Not listed |
| M003 | Benzethonium chloride Plus Dyclonine hydrochloride (Kroger Co.) | Liquid | Not listed |
Safety Considerations
Please refer to the package insert for safety information. No drug-interaction records were found for dyclonine.
Conclusion and Next Steps
Decision: Hold
Rationale: The bronchitis prediction rests on the model score alone (evidence level L5). There are no clinical trials or publications, no established mechanism, and no evidence that a topical formulation can reach the airways.
To proceed, the following is needed:
- Mechanism of action data (MOA) and a plausible pathway to airway or cough-reflex modulation
- Package insert warnings and contraindications, which are needed for safety screening
- Preclinical or exploratory clinical evidence in bronchitis or cough
- A route and formulation feasibility assessment for airway delivery
- Approved indication text for the listed licences, to confirm the original indication
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.